|
Y 4.F 49:S.HRG.117-847
|
The President's 2022 trade policy agenda : hearing before the Committee on Finance, United States Senate, One Hundred Seventeenth Congress, second session, March 31, 2022 |
1 |
|
Y 4.F 49:S.PRT.
|
Rules of procedure |
1 |
|
Y 4.F 49:S.PRT.102-95
|
Technical explanation of the amendment to title XIX of H.R. 776 (Comprehensive National Energy Act) |
1 |
|
Y 4.F 49:S.PRT.102-137
|
Legislative calendar |
1 |
|
Y 4.F 49:S.PRT.103-37
|
Fiscal year 1994 budget reconciliation recommendations of the Committee on Finance : as submitted to the Committee on the Budget pursuant to H. Con. Res. 64 |
1 |
|
Y 4.F 49:S.PRT.103-80
|
Program descriptions and general budget information for fiscal year 1995 |
1 |
|
Y 4.F 49:S.PRT.103-119
|
Legislative calendar |
1 |
|
Y 4.F 49:S.PRT.104-5
|
Rules of procedure |
1 |
|
Y 4.F 49:S.PRT.107-30
|
Restoring Earnings to Lift Individuals and Empower Families (Relief) Act of 2001 : technical explanation of provisions approved by the committee on May 15, 2001 |
1 |
|
Y 4.F 49:S.PRT.108-32
|
Technical explanation of the Energy Tax Incentives Act of 2003 : to accompany Senate Amendment 1424 |
1 |
|
Y 4.F 49:S.PRT.108-53
|
Description of the John Breaux Elder Justice Act : technical explanation of provisions approved by the Committee on September 20, 2004 |
1 |
|
Y 4.F 49:S.PRT.109-45
|
Committee staff report to the chairman and ranking member : review of the FDA's approval process for the vagus nerve stimulation therapy system for treatment-resistant depression |
1 |
|
Y 4.F 49:S.PRT.109-68
|
Minority staff report |
1 |
|
Y 4.F 49:S.PRT.110-10
|
Trade promotion authority annotated : including procedural provisions from the Trade Act of 1974 and the Trade Act of 2002 as amended |
1 |
|
Y 4.F 49:S.PRT.110-21
|
Committee staff report to the chairman and ranking member : use of educational grants by pharmaceutical manufacturers |
1 |
|
Y 4.F 49:S.PRT.110-28
|
The firing of an SEC attorney and the investigation of Pequot Capital Management |
1 |
|
Y 4.F 49:S.PRT.111-57
|
Staff report on cardiac stent usage at St. Joseph Medical Center |
2 |
|
Y 4.F 49:S.PRT.112-20
|
Staff report on Sanofi's strategic use of third parties to influence the FDA |
2 |
|
Y 4.F 49:S.PRT.112-24
|
Staff report on home health and the Medicare therapy threshold |
2 |
|
Y 4.F 49:S.PRT.113-31
|
Staff report on comprehensive tax reform for 2015 and beyond |
2 |